Clinical trial Recruiting at 1 site Interventional Ages 60 and up

Tailored hydration using ReDS lung‑water monitoring to prevent kidney injury during coronary angiography and intervention

Official title: Clinical Study on Tailored Hydration by Remote Dielectric Sensing System to Prevent Acute Renal Injury in Elderly Patients With Renal Insufficiency After Coronary Angiography

Run by Chinese PLA General Hospital · NCT07394959 · Data updated 2026-11-12

This trial tests whether using a ReDS lung‑water monitor to guide IV fluids can lower the risk of contrast‑induced acute kidney injury in people aged 60 and older with reduced kidney function having coronary angiography or PCI.

More Coronary Artery Disease trials

Quick facts

Study typeInterventional
Ages60 Years and up
SexAll
Enrollment320 (estimated)
SponsorChinese PLA General Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedSeptember 20, 2024
Main results expectedMay 31, 2026
Study endsNovember 28, 2026
Registry record updatedFebruary 6, 2026
Trial IDNCT07394959 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 60 or older with unstable angina scheduled for coronary intervention who have chronic kidney disease (eGFR between 30 and 90 mL/min) and can provide informed consent.

Probably not a fit

Patients with severe renal failure (eGFR <30 mL/min), acute decompensated heart failure, respiratory failure, recent contrast exposure, or known contrast allergy are unlikely to benefit or are excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Elderly patients with coronary disease often have chronic kidney disease and are at risk for contrast‑induced acute kidney injury (CI‑AKI) after percutaneous coronary intervention. This randomized interventional study compares tailored hydration guided by the Remote Dielectric Sensing (ReDS) lung‑water index versus standard hydration in patients scheduled for coronary intervention. The ReDS device is used to dynamically monitor lung water and adjust infusion rates to avoid fluid overload and acute pulmonary edema while providing necessary hydration. Outcomes include perioperative CI‑AKI, acute pulmonary edema, and longer‑term major cardiovascular events and need for hemodialysis.

Why it matters

Potential benefit: If successful, this approach could reduce contrast‑related kidney injury while lowering the risk of fluid‑overload complications like pulmonary edema.

How similar studies have gone: Personalized hydration strategies and various lung‑fluid monitoring approaches have shown promise in reducing CI‑AKI in some reports, but use of ReDS guidance for this indication is relatively novel and not yet widely validated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 60 years;
* Patients with unstable angina pectoris are scheduled for percutaneous coronary intervention;
* Patients with chronic renal disease (estimated glomerular filtration rate \< 90 ml/min);
* Sign the informed consent form.

Exclusion Criteria:

* 1\. Acute decompensated severe heart failure or cardiogenic shock;
* 2\. Malignant tumors, severe renal failure (estimated glomerular filtration rate \< 30 ml/min);
* 3\. Respiratory failure;
* 4\. Used contrast media within one week;
* 5\. Have allergic to contrast medium

Where it's running

  • Chinese PLA general hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.